To validate our in silico findings within actual clinical specimens, we conducted an analysis of CD8 and α-SMA expression, as detected by multiplex immunofluorescence staining, within a local cohort of stage III NSCLC patients who received neoadjuvant immunotherapy. This evidence concerns the gene ACTA1 and non-small cell lung carcinoma.